CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
Historically, the company’s Aquadex SmartFlow® System was used to remove excess fluid in patients suffering from heart failure, helping to alleviate the burden that fluid overload has on vital organs and subsequently reducing the need for hospitalization.1 However, the benefits of Aquadex® don’t stop with heart failure. The product is clinically proven to improve outcomes in critical care and pediatric patients weighing 20 kg or more. 2,3 Nuwellis reflects the “new well” that signifies better tomorrows for patients, their families and their providers. Each can experience the transformation of care made possible by the company’s fluid management technology.
Aquadex is a smart fluid management platform that uses ultrafiltration to restore fluid balance in patients experiencing fluid overload. In
“2020 was a transformational year for our company, we grew in unexpected ways and expanded our therapeutic focus areas,” said
In conjunction with the name change, the Company’s ticker symbol listed on the NASDAQ will change from CHFS to NUWE, effective
About the Aquadex SmartFlow System
The Aquadex SmartFlow® System delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow® system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the anticipated use of the net proceeds. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
President, Chief Executive Officer and Chief Financial Officer,
1 Siddiqui WJ, et al. Heart Fail Rev. 2017 Nov;22(6):685-698.
2 Ronco C, et al. Proc (Bayl Univ Med Cent). 2020 Apr 16;0(0):1-6.
3 Menon S, et al. Clin J Am Soc Nephrol. 2019
Source: CHF Solutions, Inc.